AGRX - Agile Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.3900
+0.0200 (+1.46%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.3700
Open1.3800
Bid1.3000 x 1800
Ask0.0000 x 1300
Day's Range1.3800 - 1.4000
52 Week Range0.2310 - 1.7000
Volume53,981
Avg. Volume204,825
Market Cap60.803M
Beta (3Y Monthly)-0.93
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Associated Press2 months ago

    Agile Therapeutics: 1Q Earnings Snapshot

    The Princeton, New Jersey-based company said it had a loss of 13 cents per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...

  • Zacks Small Cap Research3 months ago

    AGRX: Numerous Catalysts in 2019…

    Agile Therapeutics, Inc. (AGRX) is a women’s healthcare company focused on developing healthcare products to fulfill the unmet contraceptive needs of women. The company’s lead candidate product, Twirla® (AG200-15), is a once-weekly low-dose hormonal contraceptive patch that contains the active ingredients ethinyl estradiol (EE, a synthetic estrogen) and levonorgestrel (LNG, a type of progestin). The patch utilizes the company’s Skinfusion technology, which allows Twirla® to be the first contraceptive patch capable of delivering LNG across the skin in a reliable manner.

  • Associated Press3 months ago

    Agile Therapeutics: 4Q Earnings Snapshot

    The Princeton, New Jersey-based company said it had a loss of 11 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • Zacks Small Cap Research4 months ago

    AGRX: Positive Results for Twirla® Adhesion Study; NDA Resubmission in 2Q19

    On February 11, 2019, Agile Therapeutics, Inc. (AGRX) announced positive topline results for the comparative adhesion study that tested the company’s investigational low-dose once-weekly contraceptive patch (Twirla®) against Xulane®, the generic version of the contraceptive patch Ortho Evra®. The trial was designed to show non-inferiority in adhesion between Twirla® and Xulane®.

  • Zacks Small Cap Research5 months ago

    AGRX: Twirla® Adhesion Study Underway; NDA Resubmission in 2Q19…

    The meeting was held to discuss the company’s comparative wear study between Twirla® and Xulane®, the generic version of the contraceptive patch Ortho Evra®, including the specific design and success criteria. The trial is designed to show non-inferiority in adhesion between Twirla® and Xulane®. Following receipt of the official meeting minutes, Agile has initiated the adhesion study in approximately 80 healthy women with a body mass index (BMI)

  • Benzinga5 months ago

    The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks The following biotech stocks hit 52-week highs Jan. 10:  Takeda Pharmaceutical Co Ltd (NYSE: TAK*) Veracyte ...

  • Agile Therapeutics Inc (NASDAQ:AGRX): Are Analysts Optimistic?
    Simply Wall St.7 months ago

    Agile Therapeutics Inc (NASDAQ:AGRX): Are Analysts Optimistic?

    Agile Therapeutics Inc’s (NASDAQ:AGRX): Agile Therapeutics, Inc., a women’s healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. With the latest financial year loss of Read More...

  • Zacks Small Cap Research7 months ago

    AGRX: Awaiting Details of Adhesion Study for Twirla®…

    On October 9, 2018, Agile Therapeutics, Inc. (AGRX) announced that the company has concluded the formal dispute resolution with the U.S. Food and Drug Administration (FDA) regarding the complete response letter (CRL) issued for the new drug application (NDA) of Twirla®. While the FDA’s Office of New Drugs (OND) denied the company’s appeal, the agency did provide the company with a potential path to an NDA resubmission that would not include reformulating Twirla® or doing any type of bridging studies.

  • Associated Press8 months ago

    Agile Therapeutics: 3Q Earnings Snapshot

    On a per-share basis, the Princeton, New Jersey-based company said it had a loss of 11 cents. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...

  • Zacks Small Cap Research8 months ago

    AGRX: FDA Provides Path to NDA Resubmission for Twirla®…

    On October 9, 2018, Agile Therapeutics, Inc. (AGRX) announced that the company has concluded the formal dispute resolution with the U.S. Food and Drug Administration (FDA) regarding the complete response letter (CRL) issued for the new drug application (NDA) of Twirla®. While the FDA’s Office of New Drugs (OND) denied the company’s appeal, the agency did provide the company with a potential path to an NDA resubmission that would not include reformulating Twirla® or doing any type of bridging studies.

  • Does Agile Therapeutics Inc (NASDAQ:AGRX) Fall With The Market?
    Simply Wall St.9 months ago

    Does Agile Therapeutics Inc (NASDAQ:AGRX) Fall With The Market?

    If you’re interested in Agile Therapeutics Inc (NASDAQ:AGRX), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock couldRead More...

  • Zacks Small Cap Research10 months ago

    AGRX: Formal Dispute Resolution Continues to Office of New Drugs…

    On July 24, 2018, Agile Therapeutics, Inc. (AGRX) announced that the FDA’s Office of Drug Evaluation III (ODEIII) has denied the company’s appeal of the complete response letter issued for the new drug application of Twirla®. The company is planning to appeal the decision of the ODEIII to the Office of New Drugs. FDA regulations for dispute resolution are governed by 21 CFR 10.75, which provides a mechanism whereby an applicant can obtain formal review of any FDA decision by the employee’s supervisor.

  • Associated Press11 months ago

    Agile Therapeutics: 2Q Earnings Snapshot

    The Princeton, New Jersey-based company said it had a loss of 16 cents per share. The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...